Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR3466)
Drug Name
Tecarfarin
Synonyms ATI-5923
Indication Cerebral ischaemia [ICD11: 8B1Z] Phase 3 [1]
Thrombosis [ICD11: ICD11: DB61-GB90] Phase 3 [2]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 460.3 Topological Polar Surface Area 72.8
Heavy Atom Count 32 Rotatable Bond Count 5
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 11
Cross-matching ID
PubChem CID
54718618
CAS Number
867257-26-9
TTD Drug ID
D07VIB
Formula
C21H14F6O5
Canonical SMILES
CC(C(F)(F)F)(C(F)(F)F)OC(=O)C1=CC=C(C=C1)CC2=C(C3=CC=CC=C3OC2=O)O
InChI
InChI=1S/C21H14F6O5/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30/h2-9,28H,10H2,1H3
InChIKey
QFLNTQDOVCLQKW-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
ATI-5900 DM016179
54706454
Unclear - Unclear 1 [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR013885 Tecarfarin ATI-5900 Unclear - Unclear ES [3]
References
1 ClinicalTrials.gov (NCT02522221) Tecarfarin Anti-Coagulation Trial (TACT).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.